In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells

Journal of Drugs in Dermatology

Volumn 11, Issue 5, 2012, Pages 587-592

  De Oliveira, Jaqueline Carvalho ^a   Brassesco, María Sol ^a   Pezuk, Julia Alejandra ^a   Morales, Andressa Gois ^a   Valera, Elvis Terci ^a   Montaldi, Ana Paula ^a   Sakamoto Hojo, Elza Tiemi ^a   Scrideli, Carlos Alberto ^a   Tone, Luiz Gonzaga ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; POLO LIKE KINASE 1;

AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA CELL;

ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; MELANOMA; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PTERIDINES; SKIN NEOPLASMS;

EID: 84860891295     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Breslow A. Prognosis in cutaneous melanoma: tumor thickness as a guide to treatment. Pathol Annu. 1980;15:1-22.
2. Jerant AF, Johnson JT, Sheridan CD, Caffrey TJ. Early detection and treatment of skin cancer. Am Fam Physician. 2000;62:357-368, 375-356, 381-352.
3. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov. 9:643-660.
4. Winkles JA, Alberts GF. Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues. Oncogene. 2005;24:260-266. (Pubitemid 40188606)
5. Strebhardt K, Kneisel L, Linhart C, Bernd A, Kaufmann R. Prognostic value of pololike kinase expression in melanomas. JAMA. 2000;283:479-480. (Pubitemid 30062860)
6. Chopra P, Sethi G, Dastidar SG, Ray A. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics. Expert Opin Investig Drugs.19:27-43.
7. Schmit TL, Zhong W, Setaluri V, Spiegelman VS, Ahmad N. Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells. J Invest Dermatol. 2009;129:2843-2853.
8. Brassesco MS, Valera ET, Neder L, et al. Polyploidy in atypical grade II choroid plexus papilloma of the posterior fossa. Neuropathology. 2009;29:293-298.
9. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1:2315-2319.
10. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-408. (Pubitemid 34164012)
11. Bajetta E, Del Vecchio M, Bernard-Marty C, et al. Metastatic melanoma: chemotherapy. Semin Oncol. 2002;29:427-445. (Pubitemid 35178282)
12. Toren KL, Parlette EC. Managing melanoma in situ. Semin Cutan Med Surg. 29:258-263.
13. Kirkwood JM, Moschos S, Wang W. Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations. Clin Cancer Res. 2006;12:2331s-2336s.
14. Renner AG, Dos Santos C, Recher C, et al. Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood. 2009;114:659-662.
15. Pezuk JA, Brassesco MS, Oliveira JC, et al. Antiproliferative in vitro effects of BI 2536-mediated PLK1 inhibition on cervical adenocarcinoma cells. Clin Exp Med.
16. Morales AG, Brassesco MS, Pezuk JA, et al. BI 2536-mediated PLK1 inhibition suppresses HOS and MG-63 osteosarcoma cell line growth and clonogenicity. Anticancer Drugs. 22:995-1001.
17. Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet. 2007;369:1742-1757. (Pubitemid 46755391)
18. Kneisel L, Strebhardt K, Bernd A, Wolter M, Binder A, Kaufmann R. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol. 2002;29:354-358.
19. Liu L, Zou P, Zhang M, Tian L, Liu F. Effect of polo-like kinase 1 gene silence on cell cycle and drug resistance in K562/A02 cell. Chin Med J (Engl). 2006;119:605-608. (Pubitemid 43796868)
20. Meier F, Satyamoorthy K, Nesbit M, et al. Molecular events in melanoma development and progression. Front Biosci. 1998;3:D1005-1010.
21. Lenart P, Petronczki M, Steegmaier M, et al. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of pololike kinase 1. Curr Biol. 2007. 17:304-315.
22. Steegmaier M, Hoffmann M, Baum A, et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol. 2007;17:316-322. (Pubitemid 46241881)
23. Frost A, Mross K, Steinbild S, et al. Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours. Curr Oncol. 19:e28-35.
24. Hofheinz RD, Al-Batran SE, Hochhaus A, et al. An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. Clin Cancer Res. 16:4666-4674.
25. Mross K, Frost A, Steinbild S, et al. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2008;26:5511-5517.
26. Sebastian M, Reck M, Waller CF, et al. The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV nonsmall cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial. J Thorac Oncol. 5:1060-1067.
27. Schoffski P, Blay JY, De Greve J, et al. Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). Eur J Cancer. 46:2206-2215.